Immatics

Moderna, Immatics agree to a cancer-focused collab that could top $1.7B
Moderna, Immatics agree to a cancer-focused collab that could top $1.7B
Medical Marketing and Media
Moderna Therapeutics
Immatics
cancer
Flag link:
GSK's cell therapy retreat hits another partner as drugmaker exits Immatics collaboration
GSK's cell therapy retreat hits another partner as drugmaker exits Immatics collaboration
Endpoints
GSK
cell therapy
Immatics
Flag link:
BMS-backed Immatics' cell therapy shows early promise in small data set, prompting $110M offering
BMS-backed Immatics' cell therapy shows early promise in small data set, prompting $110M offering
Fierce Biotech
Bristol Myers Squibb
Immatics
cell therapy
clinical trials
solid tumors
Flag link:
Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
Immatics and Editas join up to bring CRISPR to 'gamma delta' cell therapy
BioPharma Dive
Editas Medicine
CRISPR
gene editing
Immatics
gamma delta cell therapy
Flag link:
New Month, New Collaborations: BMS, Sorrento & Others Announce New Alliances
New Month, New Collaborations: BMS, Sorrento & Others Announce New Alliances
BioSpace
Bristol Myers Squibb
Immatics
Sorrento Therapeutics
prostate cancer
clinical trials
Caris Life Sciences
precision medicine
Flag link:
Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks
Bristol Myers triples-down on Immatics, bringing deal to $4.2B total biobucks
Fierce Biotech
Bristol Myers Squibb
Immatics
SPAC
immunotherapy
drug discovery
biobucks
Flag link:
Bristol Myers returns to Immatics for a dual-targeting cancer drug
Bristol Myers returns to Immatics for a dual-targeting cancer drug
BioPharma Dive
Bristol Myers Squibb
Immatics
cancer
immunotherapy
Flag link:
Immatics' cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?
Immatics' cell therapy blasts solid tumors in phase 1, but durability spooks investors. Will dialing up the dose help?
Fierce Biotech
Immatics
cell therapy
solid tumors
clinical trials
Flag link:
Immatics takes up the SPAC baton
Immatics takes up the SPAC baton
EP Vantage
SPAC
Immunovant
Immatics
Flag link:
Immunocore IPO filing reveals kickback scheme, Immatics row and phishing attacks
Immunocore IPO filing reveals kickback scheme, Immatics row and phishing attacks
Fierce Biotech
Immunocore
IPOs
kickbacks
Immatics
Flag link:
Biotech GSK's cell therapy R&D lead jumps ship to partner Immatics
Biotech GSK's cell therapy R&D lead jumps ship to partner Immatics
Fierce Biotech
GSK
R&D
Immatics
Flag link:
A Covid-19 threat to business acquisitions
A Covid-19 threat to business acquisitions
EP Vantage
COVID-19
M&A
AbbVie
Allergan
Arya Sciences
Immatics
AcelRx
Tetraphase
Gilead Sciences
Forty Seven
Thermo Fisher
Stryker
Wright Medical
Flag link:
GSK pays $50M for 2 solid tumor cell therapies from Immatics
GSK pays $50M for 2 solid tumor cell therapies from Immatics
Pharmaceutical Business Review
GSK
solid tumors
cell therapies
Immatics
Flag link:
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Celgene Adds Cell Therapies From Immatics With Bristol Sale in Sight
Xconomy
Celgene
cell therapies
drug development
Immatics
cancer
Flag link:
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Genmab puts down $54M for immunotherapy collaboration — ready to spend millions more
Endpoints
Genmab
JNJ
Europe
cancer immunotherapy
Immatics
Flag link:
Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer
Amgen-partnered Immatics bags a $58M round to fund its first clinical steps on new T-cell tech for cancer
Endpoints
Amgen
Immatics
T-cells
Flag link:
Amgen, Immatics In Cancer Drug Partnership
Amgen, Immatics In Cancer Drug Partnership
Investopedia
Amgen
Immatics
bispecific antibodies
R&D
cancer
Flag link: